2025 Q4 -tulosraportti
Vain PDF
14 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 min sittenWe should probably have a joint Christmas party or something eventually 😅🍻
·11 min sittenToday's news briefly summarized: Circio will now test the delivery of circVec using peptides. This will happen in collaboration with the University of Santiago under their "TraffikGene" project. Previously, circVec has been tested with AAV (virus-based delivery system), and has an ongoing LNP collaboration with Acuitas in the CAR-T study. LNP is like a microscopic fat bubble that can transport genetic material to the cells. We don't have data from this yet. I personally find LNP very interesting. With today's news, we thus learn that Circio is exploring yet another delivery platform for circVec, and it doesn't stop there. With the help of "peptide carriers", they will also explore delivery to new tissues they haven't tested before, possibly on tissues that the other two delivery platforms don't target as well. In the long term, this could develop into new disease models and even more indications. All in all, today's news strengthens the fact that circVec is a platform technology that can potentially be used for multiple purposes with the help of various tools. The CEO's goal at the start of the year was to secure more collaboration agreements and research fields, and they have truly delivered here. Today's news is the third collaboration agreement in a short time and actively expands circVec's ecosystem. If circVec works equally well across AAV, LNP and peptide carriers, then this strengthens the platform immensely.
·6 min sittenThe value of circio as an acquisition candidate has strengthened significantly.
·1 t sittenSecond day with good news in a row, so then it will probably be a blood-red day... figure that out if you can 🫣
·44 min sittenIt seems that one is accelerating strongly after the emission, as collaboration agreements and news are coming almost daily. The 250 mill. have really gotten legs to walk on. Acquisition or licensing, whatever it ends up being in the end, now seems to be happening much faster than 24 months into the future. Is Big Pharma willing to wait until autumn before the first bid comes?
·1 min sitten · MuokattuI'll bet a whole foamy Bavarian beer that Big Pharma doesn't know their place. And it wouldn't surprise me either if Circio is not at all interested in being acquired - because here, one clearly knows its own worth. This company is a future behemoth. And just an independent AI-free thought: how many have considered whether the massive share issues, among other things, have aimed to reject forced acquisitions from foreign usurpers? Internally at Circio, one could actually have a desire to grow and exist free and independent. That perspective will probably disappoint many investors. Personally, I would prefer an independent Circio, but if they sell themselves to the highest bidder, then that's their own choice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
14 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 min sittenWe should probably have a joint Christmas party or something eventually 😅🍻
- ·11 min sittenToday's news briefly summarized: Circio will now test the delivery of circVec using peptides. This will happen in collaboration with the University of Santiago under their "TraffikGene" project. Previously, circVec has been tested with AAV (virus-based delivery system), and has an ongoing LNP collaboration with Acuitas in the CAR-T study. LNP is like a microscopic fat bubble that can transport genetic material to the cells. We don't have data from this yet. I personally find LNP very interesting. With today's news, we thus learn that Circio is exploring yet another delivery platform for circVec, and it doesn't stop there. With the help of "peptide carriers", they will also explore delivery to new tissues they haven't tested before, possibly on tissues that the other two delivery platforms don't target as well. In the long term, this could develop into new disease models and even more indications. All in all, today's news strengthens the fact that circVec is a platform technology that can potentially be used for multiple purposes with the help of various tools. The CEO's goal at the start of the year was to secure more collaboration agreements and research fields, and they have truly delivered here. Today's news is the third collaboration agreement in a short time and actively expands circVec's ecosystem. If circVec works equally well across AAV, LNP and peptide carriers, then this strengthens the platform immensely.·6 min sittenThe value of circio as an acquisition candidate has strengthened significantly.
- ·1 t sittenSecond day with good news in a row, so then it will probably be a blood-red day... figure that out if you can 🫣·44 min sittenIt seems that one is accelerating strongly after the emission, as collaboration agreements and news are coming almost daily. The 250 mill. have really gotten legs to walk on. Acquisition or licensing, whatever it ends up being in the end, now seems to be happening much faster than 24 months into the future. Is Big Pharma willing to wait until autumn before the first bid comes?·1 min sitten · MuokattuI'll bet a whole foamy Bavarian beer that Big Pharma doesn't know their place. And it wouldn't surprise me either if Circio is not at all interested in being acquired - because here, one clearly knows its own worth. This company is a future behemoth. And just an independent AI-free thought: how many have considered whether the massive share issues, among other things, have aimed to reject forced acquisitions from foreign usurpers? Internally at Circio, one could actually have a desire to grow and exist free and independent. That perspective will probably disappoint many investors. Personally, I would prefer an independent Circio, but if they sell themselves to the highest bidder, then that's their own choice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
14 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 min sittenWe should probably have a joint Christmas party or something eventually 😅🍻
- ·11 min sittenToday's news briefly summarized: Circio will now test the delivery of circVec using peptides. This will happen in collaboration with the University of Santiago under their "TraffikGene" project. Previously, circVec has been tested with AAV (virus-based delivery system), and has an ongoing LNP collaboration with Acuitas in the CAR-T study. LNP is like a microscopic fat bubble that can transport genetic material to the cells. We don't have data from this yet. I personally find LNP very interesting. With today's news, we thus learn that Circio is exploring yet another delivery platform for circVec, and it doesn't stop there. With the help of "peptide carriers", they will also explore delivery to new tissues they haven't tested before, possibly on tissues that the other two delivery platforms don't target as well. In the long term, this could develop into new disease models and even more indications. All in all, today's news strengthens the fact that circVec is a platform technology that can potentially be used for multiple purposes with the help of various tools. The CEO's goal at the start of the year was to secure more collaboration agreements and research fields, and they have truly delivered here. Today's news is the third collaboration agreement in a short time and actively expands circVec's ecosystem. If circVec works equally well across AAV, LNP and peptide carriers, then this strengthens the platform immensely.·6 min sittenThe value of circio as an acquisition candidate has strengthened significantly.
- ·1 t sittenSecond day with good news in a row, so then it will probably be a blood-red day... figure that out if you can 🫣·44 min sittenIt seems that one is accelerating strongly after the emission, as collaboration agreements and news are coming almost daily. The 250 mill. have really gotten legs to walk on. Acquisition or licensing, whatever it ends up being in the end, now seems to be happening much faster than 24 months into the future. Is Big Pharma willing to wait until autumn before the first bid comes?·1 min sitten · MuokattuI'll bet a whole foamy Bavarian beer that Big Pharma doesn't know their place. And it wouldn't surprise me either if Circio is not at all interested in being acquired - because here, one clearly knows its own worth. This company is a future behemoth. And just an independent AI-free thought: how many have considered whether the massive share issues, among other things, have aimed to reject forced acquisitions from foreign usurpers? Internally at Circio, one could actually have a desire to grow and exist free and independent. That perspective will probably disappoint many investors. Personally, I would prefer an independent Circio, but if they sell themselves to the highest bidder, then that's their own choice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt